Soligenix appoints new senior vice president

Late-stage biopharmaceutical company Soligenix, Inc., which creates vaccines for certain bioterrorism agents, has appointed Kevin Horgan as its chief medical officer and senior vice president.

Dr. Horgan has a research background in cellular immunology and is also a board certified gastroenterologist. His work with Merck lead to the development of EMEND(R), the first neurokinin-1 receptor antagonist to prevent the nausea and vomiting induced by chemotherapy.

Horgan will lead the clinical research of Soligenix with their phase 3 clinical trial of orBec(R) which is meant to treat gastrointestinal GVHD.

"We are delighted to welcome Kevin to our team, as he will leverage his extensive drug development expertise in leading our GVHD and gastrointestinal clinical programs," Christopher J. Schaber, president and CEO of Soligenix, said. "His clinical experience with gastrointestinal inflammation and a background in cellular immunology will be instrumental to us as we advance orBec(R) to Phase 3 completion in acute GI GVHD and beyond."

Dr. Horgan's training includes an immunology research fellowship with the National Cancer Institute, a fellowship in gastroenterology at the University of California - Los Angeles, and an assistant professorship of Medicine at UCLA.

Soligenix is currently developing biomedical countermeasures through their Biodefense Division to counter the effects of the ricin toxin. The RiVax ricin vaccine is part of a $9.4 million NIAID grant given to the company to develop the new vaccine.